Laura A Marlow1, Stephen D Rohl1, James L Miller1, Jeffery A Knauf2,3, James A Fagin2,3, Mabel Ryder1,4, Dragana Milosevic5, Brian C Netzel5, Stefan K Grebe5, Honey V Reddi6, Robert C Smallridge1,7, John A Copland1. 1. Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida. 2. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota. 5. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 6. Jackson Laboratory of Genomic Medicine, Farmington, Connecticut. 7. Division of Endocrinology, Internal Medicine Department, Mayo Clinic, Jacksonville, Florida.
Abstract
Objective: To investigate the molecular underpinnings of thyroid cancer, preclinical cell line models are crucial; however, ∼40% of these have been proven to be either duplicates of existing thyroid lines or even nonthyroid-derived lines or are not derived from humans at all. Therefore, we set out to establish procedures and guidelines that should proactively avoid these problems, which facilitated the creation of criteria to make valid preclinical models for thyroid cancer research. Design: Based on our recommendations, we systematically characterized all new cell lines that we generated by a standardized approach that included (1) determination of human origin, (2) exclusion of lymphoma, (3) DNA fingerprinting and histological comparisons to establish linkage to presumed tissue of origin, (4) examining thyroid differentiation by screening two to three thyroid markers, (5) examination of biological behavior (growth rate, tumorigenicity), and (6) presence of common thyroid cancer genetic changes (TP53, BRAF, PTEN, PIK3CA, RAS, TERT promoter, RET/PTC, PAX8/PPARγ, NF1, and EIF1AX). Results: We established seven new thyroid cell lines (LAM136, EAM306, SDAR1, SDAR2, JEM493, THJ529, and THJ560) out of 294 primary culture attempts, and 10 patient-derived tumor xenografts (PDTXs; MC-Th-95, MC-Th-374, MC-Th-467, MC-Th-491, MC-Th-493, MC-Th-504, MC-Th-524, MC-Th-529, MC-Th-560, and MC-Th-562) out of 67 attempts. All were successfully validated by our protocols. Conclusions: This standardized approach for cell line and PDTX characterization should prevent (or detect) future cross-contamination and ensure that only valid preclinical models are used for thyroid cancer research.
Objective: To investigate the molecular underpinnings of thyroid cancer, preclinical cell line models are crucial; however, ∼40% of these have been proven to be either duplicates of existing thyroid lines or even nonthyroid-derived lines or are not derived from humans at all. Therefore, we set out to establish procedures and guidelines that should proactively avoid these problems, which facilitated the creation of criteria to make valid preclinical models for thyroid cancer research. Design: Based on our recommendations, we systematically characterized all new cell lines that we generated by a standardized approach that included (1) determination of human origin, (2) exclusion of lymphoma, (3) DNA fingerprinting and histological comparisons to establish linkage to presumed tissue of origin, (4) examining thyroid differentiation by screening two to three thyroid markers, (5) examination of biological behavior (growth rate, tumorigenicity), and (6) presence of common thyroid cancer genetic changes (TP53, BRAF, PTEN, PIK3CA, RAS, TERT promoter, RET/PTC, PAX8/PPARγ, NF1, and EIF1AX). Results: We established seven new thyroid cell lines (LAM136, EAM306, SDAR1, SDAR2, JEM493, THJ529, and THJ560) out of 294 primary culture attempts, and 10 patient-derived tumor xenografts (PDTXs; MC-Th-95, MC-Th-374, MC-Th-467, MC-Th-491, MC-Th-493, MC-Th-504, MC-Th-524, MC-Th-529, MC-Th-560, and MC-Th-562) out of 67 attempts. All were successfully validated by our protocols. Conclusions: This standardized approach for cell line and PDTX characterization should prevent (or detect) future cross-contamination and ensure that only valid preclinical models are used for thyroid cancer research.
Authors: T Dahlman; E Lammerts; M Wik; D Bergström; L Grimelius; K Westermark; K Rubin; N E Heldin Journal: J Pathol Date: 2000-08 Impact factor: 7.996
Authors: Christina A von Roemeling; Laura A Marlow; Anthony B Pinkerton; Angela Crist; James Miller; Han W Tun; Robert C Smallridge; John A Copland Journal: J Clin Endocrinol Metab Date: 2015-02-12 Impact factor: 5.958
Authors: Erik Wennerberg; Aline Pfefferle; Lars Ekblad; Yuya Yoshimoto; Veronika Kremer; Vitaliy O Kaminskyy; C Christofer Juhlin; Anders Höög; Inger Bodin; Vitalijs Svjatoha; Catharina Larsson; Jan Zedenius; Johan Wennerberg; Andreas Lundqvist Journal: Clin Cancer Res Date: 2014-09-11 Impact factor: 12.531
Authors: Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen Journal: Mol Cancer Res Date: 2019-02-07 Impact factor: 5.852
Authors: Iñigo Landa; Nikita Pozdeyev; Christopher Korch; Laura A Marlow; Robert C Smallridge; John A Copland; Ying C Henderson; Stephen Y Lai; Gary L Clayman; Naoyoshi Onoda; Aik Choon Tan; Maria E R Garcia-Rendueles; Jeffrey A Knauf; Bryan R Haugen; James A Fagin; Rebecca E Schweppe Journal: Clin Cancer Res Date: 2019-02-08 Impact factor: 12.531
Authors: Anastasios Maniakas; Ying C Henderson; Hu Hei; Shaohua Peng; Yunyun Chen; Yujie Jiang; Shuangxi Ji; Maria Cardenas; Yulun Chiu; Diana Bell; Michelle D Williams; Marie-Claude Hofmann; Steve E Scherer; David A Wheeler; Naifa L Busaidy; Ramona Dadu; Jennifer R Wang; Maria E Cabanillas; Mark Zafereo; Faye M Johnson; Stephen Y Lai Journal: J Clin Endocrinol Metab Date: 2021-10-21 Impact factor: 6.134